Molecular Markers in Sex Hormone Pathway Genes Associated with the Efficacy of Androgen-Deprivation Therapy for Prostate Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Yu, Chia Cheng ^a,b,c   Huang, Shu Pin ^d,e   Lee, Yung Chin ^d,e   Huang, Chao Yuan ^f   Liu, Chia Chu ^d,e   Hour, Tzyh Chyuan ^g   Huang, Chun Nung ^d,e   You, Bang Jau ^h   Chang, Ta Yuan ^h   Huang, Chun Hsiung ^d,e   Bao, Bo Ying ^h,i  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b TAJEN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

ⁱ CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AROMATASE; SEX HORMONE;

AGED; AKR1C3; ANDROGEN DEPRIVATION THERAPY; ANDROGEN METABOLISM; ANDROGEN RECEPTOR GENE; ARTICLE; CAG REPEAT; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYP19A1 GENE; ESTROGEN METABOLISM; GENE; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME;

AGED; ANDROGEN ANTAGONISTS; GENETIC MARKERS; GONADAL STEROID HORMONES; HUMANS; MALE; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84872875318     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054627     Document Type: Article

References (42)

1. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, et al. (1991) Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48: 189-193.
2. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, et al. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315-4319.
3. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, et al. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59: 2511-2515.
4. Geller J, Albert JD, Nachtsheim DA, Loza D, (1984) Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 132: 693-696.
5. Cunningham JM, Hebbring SJ, McDonnell SK, Cicek MS, Christensen GB, et al. (2007) Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer. Cancer Epidemiol Biomarkers Prev 16: 969-978.
6. Lindstrom S, Zheng SL, Wiklund F, Jonsson BA, Adami HO, et al. (2006) Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate 66: 1729-1743.
7. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, et al. (2008) Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 26: 842-847.
8. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, et al. (2011) SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 29: 2565-2573.
9. Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, et al. (2012) Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy. Int J Cancer 130: 876-884.
10. Bao BY, Pao JB, Huang CN, Pu YS, Chang TY, et al. (2011) Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res 17: 928-936.
11. Huang CN, Huang SP, Pao JB, Chang TY, Lan YH, et al. (2012) Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann Oncol 23: 707-713.
12. Huang CN, Huang SP, Pao JB, Hour TC, Chang TY, et al. (2012) Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. J Intern Med 271: 499-509.
13. Huang SP, Bao BY, Hour TC, Huang CY, Yu CC, et al. (2012) Genetic Variants in CASP3, BMP5, and IRS2 Genes May Influence Survival in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy. PLOS One 7: e41219.
14. Pao JB, Yang YP, Huang CN, Huang SP, Hour TC, et al. (2011) Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer. World J Urol. doi:10.1007/s00345-011-0813-x.
15. Stewart AJ, Scher HI, Chen MH, McLeod DG, Carroll PR, et al. (2005) Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 23: 6556-6560.
16. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE, (2002) Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 168: 995-1000.
17. Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, et al. (2009) Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 115: 981-987.
18. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, et al. (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 24: 3984-3990.
19. Zhang HP, Singer B (2010) Recursive partitioning and applications. New York: Springer.
20. Storey JD, Tibshirani R, (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100: 9440-9445.
21. Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA, et al. (1997) Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol 11: 1971-1984.
22. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA, (2011) Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med 17: 657-664.
23. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, et al. (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66: 2815-2825.
24. Penning TM, Jin Y, Rizner TL, Bauman DR, (2008) Pre-receptor regulation of the androgen receptor. Mol Cell Endocrinol 281: 1-8.
25. Yuan HY, Chiou JJ, Tseng WH, Liu CH, Liu CK, et al. (2006) FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 34: W635-641.
26. Figueroa JD, Malats N, Garcia-Closas M, Real FX, Silverman D, et al. (2008) Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 29: 1955-1962.
27. Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, et al. (2004) Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 25: 2177-2181.
28. Chamberlain NL, Driver ED, Miesfeld RL, (1994) The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22: 3181-3186.
29. Hakimi JM, Schoenberg MP, Rondinelli RH, Piantadosi S, Barrack ER, (1997) Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res 3: 1599-1608.
30. Abdel-Wahab M, Berkey BA, Krishan A, O'Brien T, Hammond E, et al. (2006) Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. Am J Clin Oncol 29: 14-20.
31. Suzuki H, Akakura K, Komiya A, Ueda T, Imamoto T, et al. (2002) CAG polymorphic repeat lengths in androgen receptor gene among Japanese prostate cancer patients: potential predictor of prognosis after endocrine therapy. Prostate 51: 219-224.
32. Bratt O, Borg A, Kristoffersson U, Lundgren R, Zhang QX, et al. (1999) CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 81: 672-676.
33. Shimbo M, Suzuki H, Kamiya N, Imamoto T, Komiya A, et al. (2005) CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer. Eur Urol 47: 557-563.
34. Edwards SM, Badzioch MD, Minter R, Hamoudi R, Collins N, et al. (1999) Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer 84: 458-465.
35. Hardy DO, Scher HI, Bogenreider T, Sabbatini P, Zhang ZF, et al. (1996) Androgen receptor CAG repeat lengths in prostate cancer: correlation with age of onset. J Clin Endocrinol Metab 81: 4400-4405.
36. Klotz L, Correia A, Zhang W, (2005) The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer Prostatic Dis 8: 179-183.
37. Misra D, Xie W, Regan MM, Ross RW, Lee GS, et al. (2011) Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU Int 108: 1086-1091.
38. Sircar K, Gottlieb B, Alvarado C, Aprikian A, Beitel LK, et al. (2007) Androgen receptor CAG repeat length contraction in diseased and non-diseased prostatic tissues. Prostate Cancer Prostatic Dis 10: 360-368.
39. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, et al. (2008) Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A 105: 12182-12187.
40. Imamoto T, Suzuki H, Akakura K, Komiya A, Nakamachi H, et al. (2001) Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 48: 573-578.
41. Palmberg C, Koivisto P, Kakkola L, Tammela TL, Kallioniemi OP, et al. (2000) Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164: 1992-1995.
42. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R, et al. (1996) Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 77: 934-940.